InPress Technologies is a medical device company working toward a solution to postpartum hemorrhage (PPH,) the number one cause of maternal death. Our single-minded focus is to improve radically the treatment path for postpartum hemorrhage from the traumatic, life-altering condition that it is today. With our simple, non-invasive device, we are devoted to improving the lives of women around the world.
InPress Technologies is a company-in-residence at the Fogarty Institute for Innovation (FII,) in Mountain View CA. FII is a catalyst for medical device innovation and provides intellectual and physical resources to early-stage innovators whose ideas have significant technical merit and a high potential of improving the lives of people around the world. In July 2014, InPress was the recipient of the Lefteroff Innovator Award, which directly funds projects for promising new innovators working on pre-screened medical ideas. The Lefteroff Fund was developed to recognize Tracy Lefteroff for his legacy of commitment and dedication to entrepreneurship, investment and innovation in the life sciences.
InPress Technologies traces its history to Cal Poly (California Polytechnic State University) in San Luis Obispo, CA, where two biomedical engineers conceived our innovative approach to postpartum hemorrhage. Over the next couple of years, the team received extensive support from Innovation Quest, the San Luis Obispo HotHouse Accelerator, and the Cal Poly Small Business Development Center. The encouragement of these organizations helped the founders synthesize their idea further, conduct initial analyses, and outline a path to bring the product to market.
Postpartum hemorrhage (PPH) is excessive bleeding in a mother after childbirth. PPH is the leading cause of perinatal maternal death around the world—it is estimated that one woman dies from PPH every four minutes.
Clinically, 80% of the instances of PPH are caused by the failure of the uterus to contract after childbirth. This condition, known as uterine atony, leaves the blood vessels fully dilated and brings about unobstructed bleeding.
The InPress facilitates the body's natural mechanism for healing to address postpartum hemorrhage, without pharmaceuticals, hysterectomy, or other invasive surgical procedures. As opposed to merely treating the symptoms of PPH, the InPress is designed to stop bleeding by stimulating uterine contraction. When the InPress is inserted into a uterus upon childbirth, its proprietary mechanism is intended to stimulate the body's natural post-delivery response by gently contracting the uterus back to the right postpartum size.
The InPress will work quickly and effectively. It can dramatically reduce the cost of healthcare during childbirth and substantially reduce the risk of loss of life. We foresee the InPress becoming a part of the standard procedure for childbirth around the world. Our vision is to make the InPress affordable and accessible in developed and developing countries thus helping save the lives of women around the world.
"The InPress technology has the potential to change the way postpartum hemorrhage is treated and save many lives."Suellen Miller, Director of Safe Motherhood Program
"The InPress device is uniquely designed to work in concert with normal uterine mechanisms to prevent or stop PPH."Jan Segnitz, MD, OB/GYN
"Given the physiology of the uterus, the InPressDr. Rebekah Sharp, practicing OB/GYN, Michigan
device is the only approach that makes sense."
Jessie oversees all company activities. Under her leadership, the company continues to achieve significant milestones meeting the challenges of bringing a new technology to market. She has a tremendous ability to build relationships with current and potential stake holders. Jessie's has the ever-present drive, passion for learning, and agility that marks the most successful entrepreneurs.
Nathan leads the development of the InPress device from concept to commercial product. He is a successful medical device engineer with over 13 years of experience leading technology innovation, product development, managing transitions to manufacturing, and life-cycle management of life science-products. Nathan is driven to maximize the accessibility to innovative medical technology solutions in order to have the greatest impact on the patients.
Amy is our Lead Engineer. She has a Masters degree in Biomedical Engineering from Cal Poly, with an emphasis on hemorrhage control. Her experience in the medical device industry provides the necessary functional knowledge for design improvement and validation. Amy is inspirited to create innovative technology that has a positive global impact.
Kerry is the Chairman of the Board and a mentor at the Fogarty Institute for Innovation. He is a seasoned medical device start-up executive and his experience centers on bringing innovative maternal health technology to market. Kerry has raised over $40M during his leadership roles at medical devices companies and possesses expertise in market positioning, international partnership development.
After years of development, collaboration with top OBGYNs, diligent bench testing, risk analysis, and after an initial production run, InPress was ready to deploy the device in its first clinical trial. This initial study, with Ethics Committee oversight is now nearing completion. InPress Technologies is excited to share that the preliminary clinical study results of the InPress device have been successful.
Note: No regulatory approvals or clearances have yet been issued by Regulation Agencies for the InPress device to date.
InPress Technologies has developed the necessary engineering controls to ensure consistent product quality. The InPress quality system has earned the company this internationally recognized medical device certification of ISO 13485.